TAYMANS JILL M 4

What Happened

• Jill M. Taymans, VP Finance and Chief Financial Officer of Cryo-Cell International, reported an options exercise (code M) on May 28, 2026. She exercised options to acquire 7,500 shares at $3.10 per share (total $23,250) and a contemporaneous disposition of 7,500 derivative shares is also reported at $3.10 per share (total $23,250).

Key Details

• Transaction date: 2026-05-28; Filing date: 2026-05-29 (Form 4 accession 0001193125-26-248432).
• Prices and amounts: Acquired 7,500 shares @ $3.10 = $23,250; Disposed (derivative) 7,500 @ $3.10 = $23,250.
• Transaction code: M = Exercise or conversion of a derivative security.
• Shares owned after transaction: Not specified in the provided filing data.
• Notable footnotes included in the filing:
  • F1–F4: Various time-based vesting schedules for different option grants (annual or multi-tranche vesting dates).
  • F5: A grant under the 2022 Stock Incentive Plan with three tranches that also require stock-price performance hurdles ($6, $8, $10 average closing price over 20 trading days) in addition to time-based vesting.
• Timeliness: Filing appears timely (transaction 2026-05-28; Form 4 filed 2026-05-29).

Context

• The filing shows both an acquisition by exercise and a simultaneous disposition of the same number of derivative shares at the same price. That pattern commonly reflects an exercise combined with an immediate sell-to-cover or broker-assisted cashless transaction to satisfy exercise cost/tax obligations, but the Form 4 does not state the exact mechanics. This is an options exercise report rather than an open-market buy or sale of already-owned common stock.